Abstract
The aim of this experiment was to study the effects of the antioxidant drug “U-74389G” on rat model, particularly in ischemia reperfusion protocol. The beneficial or other effects of that molecule were studied estimating the mean oophoritis (OI) lesions. Materials and methods: 40 rats were used of mean weight 231.875 g. OI was evaluated 60 min after reperfusion for groups A and C and 120 min after reperfusion for groups B and D. Groups A and B were without the drug but C and D with U-74389G administration. Results were that U-74389G administration kept non-significantly increased the OI scores by 0.05±0.051 without lesions (p=0.3204). Reperfusion time kept non-significantly increased the OI scores by 0.05±0.051 also without lesions (p=0.3204). Nevertheless, U-74389G administration and reperfusion time together kept non-significantly increased the OI scores by 0.045±0.030 (p=0.1334). Conclusions: Results of this study indicate that U-74389G administration, reperfusion time and their interaction declined the increased OI scores from significant to non-significant level.
Keywords: Oophoritis, reperfusion, U-74389G.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats
Volume: 13 Issue: 2
Author(s): Constantinos Τsompos, Constantinos Panoulis, Konstantinos Τοutouzas, George Ζografos and Apostolos Papalois
Affiliation:
Keywords: Oophoritis, reperfusion, U-74389G.
Abstract: The aim of this experiment was to study the effects of the antioxidant drug “U-74389G” on rat model, particularly in ischemia reperfusion protocol. The beneficial or other effects of that molecule were studied estimating the mean oophoritis (OI) lesions. Materials and methods: 40 rats were used of mean weight 231.875 g. OI was evaluated 60 min after reperfusion for groups A and C and 120 min after reperfusion for groups B and D. Groups A and B were without the drug but C and D with U-74389G administration. Results were that U-74389G administration kept non-significantly increased the OI scores by 0.05±0.051 without lesions (p=0.3204). Reperfusion time kept non-significantly increased the OI scores by 0.05±0.051 also without lesions (p=0.3204). Nevertheless, U-74389G administration and reperfusion time together kept non-significantly increased the OI scores by 0.045±0.030 (p=0.1334). Conclusions: Results of this study indicate that U-74389G administration, reperfusion time and their interaction declined the increased OI scores from significant to non-significant level.
Export Options
About this article
Cite this article as:
Τsompos Constantinos, Panoulis Constantinos, Τοutouzas Konstantinos, Ζografos George and Papalois Apostolos, The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2014; 13 (2) . https://dx.doi.org/10.2174/1871523013666140804230111
DOI https://dx.doi.org/10.2174/1871523013666140804230111 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Roles of TRPM7 in Renal Ischemia-Reperfusion Injury
Current Protein & Peptide Science Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Current Drug Targets Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Immunosuppressive Drugs in HIV Disease
Current Topics in Medicinal Chemistry Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design New Drugs from Old Natural Compounds: Scarcely Investigated Sesquiterpenes as New Possible Therapeutic Agents
Current Medicinal Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Patents in Targets and Drugs for Unbalanced Cytokine and Chemokine Network Mediated Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry